Page last updated: 2024-08-21

alpha-aminopyridine and Lung Neoplasms

alpha-aminopyridine has been researched along with Lung Neoplasms in 208 studies

Research

Studies (208)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.48)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's100 (48.08)24.3611
2020's107 (51.44)2.80

Authors

AuthorsStudies
Guo, F; Huang, C; Huang, Y; Jiang, Y; Liu, S; Tian, Y; Wan, S; Wu, G; Yu, Y; Zhang, J; Zhu, J; Zhu, Z1
Bauer, TM; Calella, AM; de Marinis, F; Felip, E; Goto, Y; Kim, DW; Liu, G; Mazieres, J; Mok, T; Peltz, G; Polli, A; Shaw, AT; Solomon, BJ; Thurm, H2
Kang, JH; Kim, JO; Kim, MY; Shin, JY; Son, KH1
Akai, M; Demura, Y; Ishizuka, T; Jikuya, N; Kurokawa, K; Nakashima, K; Oi, M; Tada, T; Takeda, T1
Daga, H; Ebi, N; Fukuhara, T; Furuya, N; Goto, K; Hayashi, K; Hayashida, T; Ikeda, T; Ishii, G; Izumi, H; Kato, T; Kirita, K; Kobayashi, SS; Kodani, M; Kumagai, S; Kuyama, S; Liu, J; Matsumoto, S; Mori, S; Nakachi, I; Nakai, T; Nakamura, A; Niho, S; Nishino, K; Nosaki, K; Ohtsu, A; Okamoto, I; Sakai, T; Sakakibara-Konishi, J; Shibata, Y; Sugiyama, E; Taima, K; Tanaka, K; Udagawa, H; Watanabe, K; Yamasaki, A; Yoh, K; Zenke, Y1
Chang, XS; Chen, YD; Ding, KL; Liu, YF; Liu, YH; Ma, HC; Xiao, ZZ; Yu, YY; Zhang, HB; Zhao, WJ; Zhou, R; Zhu, YJ1
Canas, GC; Ginman, K; Gong, J; LaBadie, RR; Lin, S; Pelletier, K; Pithavala, YK; Winkle, P1
Abbattista, A; Bearz, A; Besse, B; Gadgeel, SM; Ou, SI; Shaw, AT; Solomon, BJ; Soo, RA; Toffalorio, F; Wiltshire, R1
Bauer, TM; Bertino, EM1
Avrillon, V; Baldacci, S; Bennouna, J; Besse, B; Bouledrak, K; Cadranel, J; Coudurier, M; Duruisseaux, M; Egenod, T; Galland-Girodet, S; Girard, N; Lamy, R; Missy, P; Moro-Sibilot, D; Odier, L; Otto, J; Prevost, A; Ricordel, C; Roch, B; Tillon-Strozyk, J; Westeel, V; Zalcman, G1
Ahle, G; Arrondeau, J; Cortot, A; De Crozals, F; Duflot-Boukobza, A; Fallet, V; Lena, H; Naltet, C; Rouby, P1
Abdel-Rahman, O; de Sousa, MJ; Fazio, N; Gervaso, L; Meneses-Medina, MI; Spada, F1
Avrillon, V; Baldacci, S; Besse, B; Cadranel, J; Clément-Duchêne, C; Cortot, AB; Cousin, S; Descourt, R; Doubre, H; Dubray-Longeras, P; Duruisseaux, M; Girard, N; Langlais, A; Mazieres, J; Mennecier, B; Merle, P; Monnet, I; Morin, F; Moro-Sibilot, D; Otto, J; Quantin, X; Ricordel, C; Schneider, S; Westeel, V1
Abdelhady, A; Ardizzoni, A; Barlesi, F; Ch Yang, J; Chen, X; DiDominick, S; Felip, E; Hyoung Kang, J; Navarro, A; Santoro, A; Simonelli, M; Stammberger, U; Su, WC1
Bai, C; Chang, J; Chen, G; Cheng, Y; Cui, J; Du, Y; Fan, Y; Fang, J; Huang, C; Li, H; Li, J; Liu, X; Liu, Z; Lu, S; Lu, Y; Pan, H; Peltz, G; Song, Y; Wang, K; Wu, YL; Yang, N; Zhang, H; Zhang, K; Zhao, H; Zhou, J; Zhou, Q1
Guo, M; He, Z; Jin, C; Li, C; Liu, S; Qiu, J; Wang, Y; Wu, D1
Chen, J; Martini, JF; Pithavala, YK; Sun, S1
Gon, Y; Hiranuma, H; Nakagawa, Y; Shimizu, T1
Ratain, MJ; Strohbehn, GW1
Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M1
Dagogo-Jack, I; Digumarthy, SR; Evangelist, M; Gainor, JF; Heist, RS; Lin, JJ; Murphy, JF; Muzikansky, A; Oxnard, GR; Rabin, MS; Shaw, AT1
Abbattista, A; Hayashi, H; Hooi Wong, C; Huat Tan, E; Kim, DW; Lin, CC; Liu, G; Martini, JF; Ou, SI; Seto, T; Solomon, BJ; Soo, RA; Toffalorio, F1
Pérol, M; Swalduz, A1
Basse, C; Pasquier, C1
Acker, A; Barth, JL; Dagogo-Jack, I; Dionne, K; Do, A; Gainor, JF; Hata, AN; Johnson, TR; Johnson, TW; Kiedrowski, LA; Lin, JJ; McTigue, MA; Mino-Kenudson, M; Nguyen-Phuong, L; Peterson, JL; Shiba-Ishii, A; Walcott, MA; Wei, P; Weinrich, SL; Yeap, BY; Yoda, S1
Baba, K; Goto, Y1
Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S1
Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L1
Kashizaki, F; Sekido, Y; Tanaka, A1
Fan, Y; Hong, Z; Jia, F; Li, G; Li, J; Li, Y; Liu, Z; Lu, S; Lu, Y; Wu, YL; Zhou, J; Zhou, Q1
Ma, W; Zhao, B1
Ignatius Ou, SH1
Bosch-Barrera, J; Cuyàs, E; Encinar, JA; Fernández-Arroyo, S; Joven, J; Menendez, JA; Verdura, S1
Akagi, K; Dotsu, Y; Gyotoku, H; Imamura, E; Mukae, H; Ono, S; Sen, T; Takemoto, S; Taniguchi, H; Yamada, T; Yamaguchi, H; Yano, S1
Falk, M; Griesinger, F; Heukamp, LC; Hövel, I; Jóri, B; Tiemann, M; Weist, P1
Abbattista, A; Dagogo-Jack, I; Do, A; Gainor, JF; Krueger, EA; Krulewicz, S; Lin, JJ; Messina, R; Murphy, JF; Peterson, J; Thurm, H; Yeap, BY1
Liu, Q; Luo, X; Peng, L; Zeng, X; Zhou, Z1
Nagasaka, M; Ou, SI2
Acker, A; Besse, B; Camidge, DR; Davare, MA; Drilon, A; Gadgeel, SM; Hata, AN; Horan, JC; Keddy, C; Kohl, NE; Lin, JJ; Mente, S; Nguyen-Phuong, L; Nicholson, KS; Ou, SI; Pelish, HE; Porter, JR; Shair, MD; Soglia, JR; Sun, Y; Tangpeerachaikul, A; van der Wekken, AJ; Yoda, S; Zhu, V1
Gainor, JF; Lin, JJ1
Planchard, D; Riudavets, M1
Jia, K; Ren, S1
Barker, K; Bellini, A; Bhalshankar, J; Calton, E; Carcaboso, AM; Che, H; Chen, L; Chesler, L; Decaudin, D; Del Nery, E; Delattre, O; Dhariwal, S; Gao, Q; Geoerger, B; George, SL; Gestraud, P; Goodman, A; Gorrini, C; Hutchinson, JC; Iddir, Y; Jamin, Y; Janoueix-Lerosey, I; Jiménez, I; Marques Da Costa, ME; Martins Da Costa, B; Nemati, F; Pierre-Eugène, C; Poon, E; Saberi-Ansari, E; Saint-Charles, A; Schleiermacher, G; Shrestha, S; Surdez, D; Tucker, ER; Tweddle, DA1
Ma, W; Wu, J; Zhao, B1
Chahine, C; Felefly, T; Ibrahim, R; Khalife, N; Saleh, K1
Horie, N; Khairunnisa, NI; Miyata, Y; Okada, M; Yamasaki, F1
Berko, ER; Casey, C; Daniels, A; Gerelus, M; Ghazarian, S; Goldsmith, KC; Gostuski, I; Kalna, J; Kennedy, A; Krytska, K; Lemmon, MA; Marachelian, A; Maris, JM; Matkar, S; Mossé, YP; Park, JR; Pavlick, D; Petrova, ZO; Radhakrishnan, R; Smith, CM; Witek, GM; Wu, MA1
Bauer, TM; Felip, E; Goto, Y; Iadeluca, L; Jassem, J; K Mok, TS; Kim, DW; Liu, G; López, FL; Marinis, F; Mazieres, J; Messina, R; Polli, A; Shaw, AT; Solomon, BJ; Soo, RA; Toffalorio, F; Wu, YL1
Kunimasa, K; Nishino, K; Wada, M1
Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S1
Higgins, GS; McGowan, DR; Skwarski, M1
van Dam, PA1
Barlesi, F; Besse, B; Demedts, I; Frimodt-Moller, B; Fuentes Pradera, J; Gazzah, A; Kim, JS; Robinet, G; Soldatenkova, V; Vansteenkiste, J1
Camidge, DR; Patil, T1
Arriola, E; Monzonís, X1
Agustoni, F; Arosio, G; Bidoli, P; Bisson, WH; Cordani, N; Cortinovis, D; Gambacorti-Passerini, C; Mologni, L; Pagni, F; Piazza, R; Sharma, GG; Villa, M1
Abbattista, A; Bauer, TM; Besse, B; Chiari, R; Clancy, JS; Kao, S; Li, S; Lin, CC; Martini, JF; Ou, SI; Peltz, G; Riely, GJ; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H1
Duruisseaux, M1
Killock, D1
Bergeron, M; Chen, J; Ginman, K; James, LP; Lee, K; Pawlak, S; Peltz, G; Pithavala, YK; Xu, H1
Fujita, N; Horiike, A; Katayama, R; Kitazono, S; Koike, S; Nishikawa, S; Nishio, M; Ohyanagi, F; Tambo, Y; Tsukahara, M; Uchibori, K; Yanagitani, N; Yoshizawa, T1
Dejust, S; El Farsaoui, K; Morland, D; Moubtakir, A; Prevost, A1
André, T; Bay, JO; Bouleuc, C; Hervé, L; Magné, N; Penel, N; Rodrigues, M; Sabatier, R; Thiery-Vuillemin, A; Wislez, M1
Abbattista, A; Bauer, TM; Felip, E; Gainor, JF; Johnson, ML; Navarro, A; Peltz, G; Pithavala, YK; Shaw, AT; Thurm, H1
Asokan, P; Atal, S; Jhaj, R1
Choo, JR; Soo, RA1
Jiang, W; Lizaso, A; Mao, X; Mi, J; Song, L; Yang, N; Zeng, L; Zhang, Y; Zhou, Y1
Das, J; Mathuram, TL; Natarajan, U; Rathinavelu, A; Venkatesan, T1
Abbattista, A; Bearz, A; Besse, B; Clancy, JS; Felip, E; Gadgeel, SM; Kao, S; Lin, CC; Masters, ET; Peltz, G; Peters, S; Reisman, A; Ross Camidge, D; Seto, T; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H1
Ang, YL; Kim, DW; Lin, CC; Lin, YT; Loong, HH; Nagasaka, M; Ock, CY; Ou, SI; Reungwetwattana, T; Soo, RA; Syn, NL; Tchekmedyian, N; To, H; Zhu, VW1
Ge, Y; Kukreja, G; Nagasaka, M; Ou, SI; Sukari, A1
Abdel-Rahman, O; El Darsa, H; Sangha, R1
Pan, D; Yan, J; Zhou, X1
Guo, L; Jin, H; Lu, L; Sun, P; Yang, X; Yang, Y; Zhang, N; Zhao, Q; Zhou, L1
Arkenau, HT; Coleman, N; Popat, S; Welsh, L; Yousaf, N1
Das, S; Say, EAT; Sioufi, K1
Aydin, K; Aydıner, A; Basal, FB; Beypınar, İ; Cabuk, D; Camidge, DR; Christopoulos, P; Cicin, I; Cinkir, HY; Coşkun, HŞ; Demirci, U; Demirkazık, A; Dudnik, E; Eralp, Y; Erman, M; Fedor, M; Filippova, E; Froesch, P; Gautschi, O; Gillis, R; Grinberg, RD; Isikdogan, A; Kaplan, MA; Karaoğlu, A; Kilickap, S; Korkmaz, T; Mazieres, J; Meydan, N; Ng, TL; Okutur, K; Olmez, OF; Orlov, S; Öztop, İ; Özyılkan, Ö; Paydas, S; Peled, N; Reguart, N; Roisman, LC; Şendur, MAN; Şenler, FÇ; Sezer, A; Tural, D; Turna, H; Yazılıtaş, D; Yıldız, I; Yilmaz, C; Yumuk, PF; Zirtiloglu, A1
Li, X; Wang, L; Yu, J1
Anyaegbu, G; Bentley, H; Bulusu, VR; Hatcher, H; Horan, G; Watkins, J; Wong, HH1
Lee, CS; Seetharamu, N; Wanchoo, R1
Feng, X; Xu, ES1
Fujiwara, Y; Naito, T; Shiraishi, H1
Liu, L; Lizaso, A; Xu, Q; Zhang, Y1
Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H1
Eisenstein, M1
Romero, D1
Huang, D; Li, T; Lizaso, A; Meng, Z; Wang, P1
Kuang, S; Leighl, NB1
Chen, J; Houk, B; Pithavala, YK; Ruiz-Garcia, A1
Chen, P; Chen, Z; Li, J; Qian, J; Wang, C; Yue, D; Zhang, B; Zhang, H; Zhang, L1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N1
Abbattista, A; Bauer, TM; Bauman, JR; Bearz, A; Besse, B; Camidge, DR; Felip, E; Peltz, G; Peters, S; Shaw, AT; Solomon, BJ; Thurm, H; Toffalorio, F; Wiltshire, R1
Stinchcombe, TE1
Camidge, DR1
Akhter, N; Kanwar, YS; McGee, K; Stone, NJ; Villaflor, V; Wadhwani, S1
Chaudhari, K; Nathany, S; Suryavanshi, M; Talwar, V1
Hara, M; Iwakami, SI; Matsuda, H; Takahashi, K1
Chen, J; Gong, J; LaBadie, RR; Li, J; Mfopou, JK; Pithavala, YK1
Chen, J; James, LP; Klamerus, KJ; Mugundu, G; O'Gorman, MT; Pithavala, YK1
Chen, J; Clancy, J; Hibma, J; James, LP; Peltz, G; Ruiz-Garcia, A; Thurm, H1
Biddle, KE; Chen, J; Finkelstein, M; Hu, W; Johnson, TR; Lettiere, D; Palazzi, X; Pithavala, YK; Thibault, S; Tse, S1
Li, H; Sun, Y; Wang, J; Xu, X1
Almond, C; Asanin, ST; Cooper, M; Iadeluca, L; Masters, ET; Nilsson, FOL; Smith, S1
Aguiar, C; Barata, F; Hespanhol, V; Marques, JB; Marques, TR1
Dunst, J; Richter, J1
Cress, WD; Gimbrone, NT; Gordián, ER; Kinose, F; Percy, TR; Rix, U; Sarcar, B; Sumi, NJ; Wright, GM1
Li, B; Li, Q; Liu, L; Sheng, Z; Song, J; Teng, L; Wang, B; Wang, L; Zhang, J1
Fukushima, T; Kanda, S; Kobayashi, T; Koizumi, T; Noguchi, T; Sekiguchi, N1
Gong, ML; Qu, GP; Shi, M; Wang, D; Wang, P; Wu, JH; Zhang, ZJ1
Chang, GC; Chen, KC; Hsu, KH; Huang, YH; Lee, PH; Tseng, JS; Yang, TY1
Ginman, K; James, LP; Nepal, S; O'Gorman, MT; Pithavala, YK; Xu, H1
Bannas, P; Beumer, N; Bokemeyer, C; Goekkurt, E; Iglauer, P; Imbusch, CD; Loges, S; Simon, R; Velthaus, JL1
Chiang, CL; Chiang, TS; Chiu, CH; Chung, HP; Hung, JY; Ku, WH; Lee, KY; Lee, MH; Lin, CB; Lin, YT; Shih, JY; Su, J; Su, WC; Tseng, YH; Wei, YF; Wu, SY1
Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M1
Chow, LQM; Crino, L; De Pas, T; Felip, E; Mok, TSK; Salgia, R; Tan, DSW1
Ashraf, Z; Basit, S; Latif, M; Lee, K1
Aerts, JG; Bezemer, K; Dammeijer, F; Hegmans, JP; Hendriks, RW; Kaijen-Lambers, ME; Lievense, LA; van Hall, T; van Nimwegen, M1
Bayo, J; Behrens, C; Bhanu, NV; Coombes, K; Dalvi, MP; Garcia, BA; Gazdar, AF; Girard, L; Heymach, JV; Kalhor, N; Kittler, R; Kollipara, RK; Martinez, ED; Minna, JD; Mino, B; Park, H; Parra, ER; Pataer, A; Rodriguez-Canales, J; Suraokar, M; Swisher, SG; Timmons, BC; Villalobos, P; Wang, L; Wistuba, II; Xie, Y; Yenerall, P; Zhong, R; Zhou, Y1
Hochmair, MJ; Prosch, H; Schwab, S1
Fan, Y; Guo, Q; Huang, Z; Li, Y; Liu, Y; Wang, T; Wang, X; Xiang, R; Xu, G; Yang, S; Zhang, C1
Kim, JW; Kim, SJ; Kim, YA; Kim, YK; Lee, HY; Lee, SH; Yeo, CD1
Ma, MJ; Mekhail, TM; Parker, JV; Yuan, C1
Ai, J; Chen, H; Chen, X; Gao, Y; Geng, M; He, Y; Li, C; Liu, H; Peng, X; Wang, J; Wang, Y; Zheng, M; Zhu, W1
Bennett, CE; Cam, H; Coss, CC; Gardner, HL; Guttridge, DC; Hariharan, S; Houghton, P; LeBlanc, AK; Lin, J; Ling, Y; London, CA; Mo, X; Phelps, MA; Ren, L; Roberts, R; Xiao, H; Yu, PY1
Kang, MJ; Lee, JH; Yun, HH1
Abbattista, A; Bauer, TM; Besse, B; Chen, J; Clancy, JS; Dietrich, J; Felip, E; Gainor, JF; James, LP; Johnson, M; Martini, JF; Navarro, A; Postel-Vinay, S; Shaw, AT; Solomon, BJ1
Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F1
Chmielewska, K; Kluska, M; Pietrzak, J; Robaszkiewicz, A; Rygielska, Ż; Tempka, D; Tokarz, P; Virág, L1
Dong, L; Li, S; Xia, J; Zhang, J; Zhang, P; Zhang, X; Zhang, Y; Zhu, N1
Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS1
Catherinot, E; Chabrol, A; Chaumais, MC; Couderc, LJ; Doubre, H; Fraboulet, S; Friard, S; Hamid, AM; Mayenga, M; Metivier, AC; Montani, D; Rivaud, E; Salvator, H; Tcherakian, C1
Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W1
Chen, XM; Tu, SS; Zhang, FB; Zhao, C; Zheng, CH1
Desai, A; Gadgeel, SM; Lisak, RP; Sriwastava, S1
Baglivo, S; Chiari, R; De Giglio, A; Ludovini, V; Metro, G; Ricciuti, B; Siggillino, A1
Betton, M; Brosseau, S; Chemouny, JM; Goujon, JM; Gounant, V; Hanouna, G; Sannier, A; Zalcman, G1
Balestra, V; Bordi, P; Facchinetti, F; Gnetti, L; Majori, M; Silini, EM; Silva, M; Tiseo, M; Ventura, L1
Amaro, MI; Cabral, LM; de Almeida, GS; de Sousa, VP; Healy, AM; Suzuki, ÉY1
Elkon, JM; Millett, RL; Tabbara, IA1
Huang, X; Li, M; Liao, W; Liu, B; Liu, J; Yin, Y; Zhu, R1
Abbattista, A; Bauer, TM; Bearz, A; Besse, B; Camidge, DR; Chen, J; Chiari, R; Clancy, JS; Felip, E; Gadgeel, SM; James, LP; Lin, CC; Martini, JF; Ou, SI; Peltz, G; Riely, GJ; Seto, T; Shaw, AT; Solomon, BJ; Soo, RA; Tan, EH; Thurm, H1
Morgensztern, D; Waqar, SN1
Facchinetti, F; Tiseo, M1
Baslan, T; Bott, MJ; Chen, CC; Chen, HA; de Stanchina, E; Fennell, M; Feucht, J; Ho, YJ; Kulick, A; Leibold, J; Lowe, SW; Manchado, E; Poirier, JT; Romesser, PB; Rudin, CM; Ruscetti, M; Salgado, NR; Sanchez-Rivera, FJ; Sherr, CJ; Tian, S1
Camidge, DR; Honce, JM; Lindquist, DL; Sakamoto, MR1
Gong, W; Yang, J1
Araki, M; Fujita, N; Horiike, A; Ishikawa, T; Kanada, R; Katayama, R; Koike, S; Ma, B; Maemondo, M; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sakashita, T; Tamai, K; Watanabe, K; Yanagitani, N1
Chang, HY; Chien, PJ; Ko, JL; Ou, CC; Wang, BY; Wu, YF1
Ahn, JS; Ahn, MJ; Choi, Y; Lee, J; Lee, SH; Park, K; Sun, JM1
Ekman, S; Hydbring, P; Jatta, K; Kacal, M; Kanony, M; Kis, L; Lai, Y; Lewensohn, R; Norberg, E; Stukan, I; Vakifahmetoglu-Norberg, H1
Akamine, T; Mori, M; Seto, T; Tagawa, T; Takeo, S; Toyokawa, G; Yamazaki, K1
Bauer, TM; Chioda, MD; Felip, E; Peltz, G; Shaw, AT; Solomon, BJ; Thurm, H1
Abbattista, A; Bauer, TM; Besse, B; Camidge, DR; Chiari, R; Clancy, JS; Felip, E; Gadgeel, SM; Kao, S; Li, S; Lin, CC; Martini, JF; Ou, SI; Riely, GJ; Satouchi, M; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H1
Bao, X; Lu, S; Niu, X; Wang, M; Wang, Q; Wang, S; Wang, Y; Xu, L; Zhang, J1
Bai, Y; Deng, L; Ding, M; Lu, D; Shao, YW; Wu, X; Yang, Y; Yu, R1
Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA1
Hochmair, M; Prosch, H; Weinlinger, C1
Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q1
Buffoni, L; Pellerino, A; Rudà, R; Soffietti, R1
Chiba, S; Goto, K; Hatanaka, Y; Ikezawa, Y; Kitai, H; Matsumoto, S; Mizugaki, H; Sakakibara-Konishi, J; Sasaki, T; Shinagawa, N; Yoshida, R1
Coleman, N; Popat, S; Wotherspoon, A; Yousaf, N1
Compter, A; de Waard, Q; Gafer, H; van den Heuvel, M1
Higo, H; Hotta, K; Ichihara, E; Kano, H; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Matsubara, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Sato, A; Tabata, M; Takata, M; Tomida, S; Toyooka, S; Watanabe, H1
Alarcon, S; Collins, J; Doroshow, JH; Kinders, RJ; Kummar, S; Lee, MJ; Park, SR; Pfister, T; Piekarz, R; Speranza, G; Steinberg, SM; Trepel, JB; Wang, L; Wright, JJ1
Chen, M; Deng, X; Khuri, FR; Li, Y; Owonikoko, TK; Ren, H; Sun, SY; Yue, P; Zhao, L1
Curran, WJ; Deng, X; Khuri, FR; Li, R; Magis, AT; Owonikoko, TK; Park, D; Ramalingam, SS; Sica, GL; Sun, SY1
Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ1
Nakagawa, T; Yano, S1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Lu, XP; Nie, LP; Ning, ZQ; Pan, DS; Shan, S; Wan, J; Yue, XP; Zhang, K; Zhang, W; Zhou, Y; Zhu, JZ1
Chen, L; Cress, WD; Kurtyka, CA1
Lam, JL; Smeal, T; Vicini, P; Wang, H; Yamazaki, S; Zou, HY1
Bryan, MC; Burdick, DJ; Chan, BK; Chen, Y; Dotson, J; Eigenbrot, C; Hanan, EJ; Heald, RA; Heffron, TP; Jackson, PS; La, H; Lainchbury, MD; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Seward, EM; Sideris, S; Tam, C; Wang, S; Yeap, SK; Yen, I; Yin, J; Yu, C; Zilberleyb, I1
Cho, JU; Choi, S; Cui, M; Kim, BH; Kim, SY; Kim, TY; Kwon, YG; Lee, H; Lee, S; Lee, Y; Yang, BS; Yoo, H1
Alfieri, RR; Ardizzoni, A; Bonelli, MA; Caffarra, C; Cavazzoni, A; Cretella, D; Falco, A; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, CA; Madeddu, D; Petronini, PG; Quaini, F; Rossetti, P; Saccani, F; Tiseo, M1
Aimone, P; Canon, JL; De Braud, F; De Pas, T; Di Tomaso, E; Dy, GK; Felip, E; Gray, JE; Gridelli, C; Grossi, F; Reck, M; Roussou, P; Soria, JC; Su, WC; Thongprasert, S; Vansteenkiste, JF; Vidam, GA; Wang, YA; Yoshioka, H1
Ichinose, Y; Seto, T; Takenoyama, M; Toyokawa, G1
Knezevic, CE; Kuenzi, BM; Remsing Rix, LL; Rix, U; Sumi, NJ1
Goldman, JW; Hurt, KC; Koustenis, A; Paz-Ares, L; Reck, M; Shi, P1
Bergqvist, S; Brooun, A; Burke, BJ; Dardaei, L; Deng, YL; Engelman, JA; Frias, RL; Friboulet, L; Gainor, JF; Getz, G; Iafrate, AJ; James, LP; Johnson, TW; Katayama, R; Le, L; Leshchiner, I; Liu, W; Logan, J; McTigue, M; Schultz, KR; Shaw, AT; Smeal, T; Timofeevski, S1
Liu, D; Savooji, J; Wu, J1
Byers, LA; Cardnell, RJ; Diao, L; Fan, Y; Feng, Y; Heymach, JV; Masrorpour, F; Mukherjee, S; Nilsson, M; Shen, Y; Stewart, CA; Tong, P; Wang, J1
Fan, XX; He, J; He, JX; Huang, J; Huang, L; Jiang, ZB; Leung, EL; Li, N; Li, X; Liu, L; Pan, H; Xie, C; Xie, Y; Yao, XJ1
Chen, JJ; Chien, PJ; Ko, JL; Lin, CH; Lin, SH; Wang, BY; Wu, YF1
Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY1
André, F; Auger, N; Besse, B; Facchinetti, F; Farace, F; Friboulet, L; Kuo, MS; Lacroix, L; Loriot, Y; Mahjoubi, L; Planchard, D; Remon, J; Scoazec, JY; Soria, JC1
Benes, CH; Channick, C; Chin, E; Dagogo-Jack, I; Dardaei, L; Dias-Santagata, D; DiCecca, RH; Digumarthy, S; Engelman, JA; Friboulet, L; Gadgeel, S; Gainor, JF; Getz, G; Heist, RS; Huynh, T; Iafrate, AJ; Katayama, R; Keyes, C; Le, LP; Lee, D; Lennerz, J; Leshchiner, I; Lockerman, E; Logan, J; Mino-Kenudson, M; Muniappan, A; Parks, M; Ritterhouse, LL; Schultz, K; Sequist, LV; Shaw, AT; Singh, M; Yoda, S1
Chen, M; Chen, T; Feng, J; Gao, L; Guo, H; Liang, Y; Liu, F; Liu, JJ; Ren, H; Shang, D; Shi, P; Thakur, A; Wang, T; Xu, F; Yang, T; Zhang, S1
Dhanasingh, I; Kanteti, R; Kindler, HL; Lennon, FE; Mambetsariev, B; Mirzapoiazova, T; Riehm, JJ; Salgia, R1
Bria, E; Brunelli, M; Caccese, M; Caliò, A; Carbognin, L; Cuppone, F; Ferrara, R; Grizzi, G; Petraglia, S; Pilotto, S; Scarpa, A; Tortora, G1
Kim, JE; Kim, W; Min, YH1
Bankovic, J; Dragoj, M; Milosevic, Z; Pesic, M; Stankovic, T; Tanic, N1
Cuccarese, MF; Dubach, JM; Engblom, C; Garris, C; Miller, MA; Pfirschke, C; Pittet, MJ; Weissleder, R1
Ali, SM; Fernandez-Rocha, MY; Gitlitz, BJ; Lee, TK; Milliken, J; Ou, SI; Pavlick, D; Schrock, AB; Young, L; Zhu, VW1
Kwok, C; Luo, H; McMahon, G; Nam, JO; Patel, N; Phillips, A; Schlaepfer, DD; Stupack, DG; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C1
Gillissen, A; Häussermann, A1
Ahn, SH; Cha, HJ; Cho, SY; Ha, JD; Han, SY; Jung, H; Kang, SY; Kim, HR; Koh, JS; Lee, CO; Lee, J; Lee, MO; Ryu, JW1
Koizumi, H; Li, Q; Matsumoto, K; Mukaida, N; Nakagawa, T; Nakamura, T; Nishioka, Y; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S1
Chen, M; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Ren, H; Sun, SY; Tao, H; Yue, P1
Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S1
Dicker, AP; Du, R; Li, B; Lu, B; Sun, Y; Torossian, A1
Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S1
Chang, RP; Giaccone, G; Harada, T; Killian, JK; Lucchi, M; Meltzer, PS; Smith, WI; Suuriniemi, M; Voortman, J; Wang, Y1
Goetsch, CA; Howard, JF; Kim, YI; Sanders, DB1

Reviews

22 review(s) available for alpha-aminopyridine and Lung Neoplasms

ArticleYear
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    BMC cancer, 2021, Nov-26, Volume: 21, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Rearrangement; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome

2021
[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]
    Bulletin du cancer, 2022, Volume: 109, Issue:4

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quality of Life

2022
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
    Current oncology reports, 2022, Volume: 24, Issue:6

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Lung Neoplasms; Neuroendocrine Tumors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma

2022
Lorlatinib as a treatment for ALK-positive lung cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:24

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2022
An update on lorlatinib: a novel first line treatment for
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:3

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases

2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
    Future oncology (London, England), 2023, Volume: 19, Issue:14

    Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors

2023
[2019 international oncology news: A compendium].
    Bulletin du cancer, 2020, Volume: 107, Issue:2

    Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Digestive System Neoplasms; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Purines

2020
Lorlatinib for the treatment of
    Expert review of anticancer therapy, 2020, Volume: 20, Issue:4

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles

2020
A user's guide to lorlatinib.
    Critical reviews in oncology/hematology, 2020, Volume: 151

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
Pharmacological and clinical properties of lorlatinib in the treatment of
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:13

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Treatment Outcome

2020
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Japanese journal of clinical oncology, 2021, Jan-01, Volume: 51, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2021
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hyperlipidemias; Lactams; Lung Neoplasms; Middle Aged; Pyrazoles

2021
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:2

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2022
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Cancer treatment reviews, 2017, Volume: 55

    Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones

2017
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Cancer treatment reviews, 2017, Volume: 55

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2017
First macrocyclic 3
    European journal of medicinal chemistry, 2017, Jul-07, Volume: 134

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Lactams; Lactams, Macrocyclic; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases

2017
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries

2018
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2019
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Cancer metastasis reviews, 2015, Volume: 34, Issue:4

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2015
Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Journal of hematology & oncology, 2016, Mar-08, Volume: 9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Kaplan-Meier Estimate; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:17

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases

2016
[Diseases of the lung and air passages 2010].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:25-26

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Indans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Phosphodiesterase 4 Inhibitors; Pneumonia, Bacterial; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones

2010

Trials

29 trial(s) available for alpha-aminopyridine and Lung Neoplasms

ArticleYear
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
    European journal of drug metabolism and pharmacokinetics, 2022, Volume: 47, Issue:2

    Topics: Adult; Aminopyridines; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Pyrazoles; Renal Insufficiency

2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022, Volume: 17, Issue:4

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Retrospective Studies

2022
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2022, Volume: 166

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022, Volume: 17, Issue:6

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crizotinib; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Taiwan

2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
    JCO precision oncology, 2022, Volume: 6

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles

2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Lung cancer (Amsterdam, Netherlands), 2022, Volume: 169

    Topics: Aminopyridines; Asian People; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2022
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2019, Volume: 137

    Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome

2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult

2019
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
    Advances in therapy, 2020, Volume: 37, Issue:2

    Topics: Adult; Aminopyridines; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Interactions; Female; Healthy Volunteers; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Rifampin; Young Adult

2020
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
    Targeted oncology, 2020, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Incidence; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Pyrazoles

2020
First-Line Lorlatinib or Crizotinib in Advanced
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Hyperlipidemias; Intention to Treat Analysis; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Pyrazoles; Survival Analysis

2020
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:2

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Healthy Volunteers; Hepatic Insufficiency; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proton Pump Inhibitors; Pyrazoles; Renal Insufficiency; Serum Albumin

2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:5

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:10

    Topics: Aminopyridines; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Healthy Volunteers; Humans; Lactams; Lung Neoplasms; Modafinil; Pyrazoles

2021
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:10

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2021
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:5

    Topics: Adult; Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypercholesterolemia; Lactams; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Risk Assessment; Treatment Outcome

2021
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
    PharmacoEconomics, 2021, Volume: 39, Issue:8

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lactams; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quality-Adjusted Life Years; Sweden

2021
Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Clinical pharmacology in drug development, 2021, Volume: 10, Issue:11

    Topics: Adult; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Interactions; Female; Food; Food-Drug Interactions; Healthy Volunteers; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrazoles; Rabeprazole; Young Adult

2021
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:12

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Rearrangement; Humans; Internationality; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Patient Selection; Prognosis; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases; Risk Assessment; Survival Analysis; Treatment Outcome

2017
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate

2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    The Lancet. Oncology, 2018, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Time Factors; Tumor Burden

2018
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 06-01, Volume: 37, Issue:16

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Risk Factors; Time Factors

2019
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 113

    Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia

2019
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:6

    Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome

2019
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cohort Studies; Colorectal Neoplasms; Endothelial Cells; Female; Head and Neck Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasms; Oxazines; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thyroid Neoplasms

2013
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:9

    Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases

2015
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati
    Clinical lung cancer, 2016, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Palliative Care; Prognosis; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Survival Rate; Young Adult

2016
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    The New England journal of medicine, 2016, Jan-07, Volume: 374, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lactams, Macrocyclic; Liver Failure; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016

Other Studies

157 other study(ies) available for alpha-aminopyridine and Lung Neoplasms

ArticleYear
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
    Journal of enzyme inhibition and medicinal chemistry, 2023, Volume: 38, Issue:1

    Topics: Anaplastic Lymphoma Kinase; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins

2023
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
    Future oncology (London, England), 2021, Dec-01, Volume: 17, Issue:34

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Language; Lung Neoplasms; Pyrazoles

2021
Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Anticancer research, 2021, Volume: 41, Issue:10

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Humans; Lung Neoplasms; Mice; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Xenograft Model Antitumor Assays

2021
Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
    Medicine, 2021, Oct-01, Volume: 100, Issue:39

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Organophosphorus Compounds; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines

2021
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
    Nature, 2021, Volume: 600, Issue:7888

    Topics: Adenocarcinoma of Lung; Aminopyridines; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Humans; Lactams; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Oncogene Proteins, Fusion; Pyrazoles; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays

2021
Podcast on the Management of Adverse Events Associated with Lorlatinib.
    Advances in therapy, 2022, Volume: 39, Issue:4

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 166

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles

2022
Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
    Anti-cancer drugs, 2022, 08-01, Volume: 33, Issue:7

    Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Tracheal Stenosis

2022
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2022
Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.
    Thoracic cancer, 2022, Volume: 13, Issue:9

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2022
Lorlatinib Exposed: A Far From Optimal Dose.
    Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:6

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2022
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:5

    Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local

2022
Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-01, Volume: 40, Issue:31

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2022
[New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].
    Bulletin du cancer, 2022, Volume: 109, Issue:9

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
    Nature cancer, 2022, Volume: 3, Issue:6

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles

2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 10-01, Volume: 40, Issue:28

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lung Neoplasms; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2022
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:11

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53

2022
Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
    Journal of medical case reports, 2022, Aug-24, Volume: 16, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Kidney Diseases; Lactams; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles

2022
[Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022, Aug-20, Volume: 25, Issue:8

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; China; Consensus; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles

2022
Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022, Volume: 17, Issue:9

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2022
In Response to Continuation of Lorlatinib Beyond Progressive Disease.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022, Volume: 17, Issue:9

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2022
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.
    International journal of molecular sciences, 2022, Sep-01, Volume: 23, Issue:17

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lactams; Lactams, Macrocyclic; Lipids; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Silybin; Tandem Mass Spectrometry; Triglycerides

2022
Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
    Cancer science, 2023, Volume: 114, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neuregulin-1; Protein Kinase Inhibitors

2023
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
    Current oncology (Toronto, Ont.), 2022, 09-16, Volume: 29, Issue:9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Tumor Suppressor Protein p53

2022
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023, Volume: 18, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors

2023
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Frontiers in public health, 2022, Volume: 10

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Crizotinib; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Sulfones

2022
CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023, Volume: 18, Issue:2

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms

2023
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
    Cancer discovery, 2023, 03-01, Volume: 13, Issue:3

    Topics: Aminopyridines; Brain; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2023
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.
    The Lancet. Respiratory medicine, 2023, Volume: 11, Issue:4

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases

2023
Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023, Volume: 18, Issue:1

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors

2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 04-03, Volume: 29, Issue:7

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Neuroblastoma; Protein Kinase Inhibitors

2023
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023, Volume: 18, Issue:3

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases

2023
The
    Future oncology (London, England), 2023, Volume: 19, Issue:4

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases

2023
The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases.
    Clinical lung cancer, 2023, Volume: 24, Issue:5

    Topics: Aminopyridines; Humans; Hypercholesterolemia; Lactams, Macrocyclic; Lung Neoplasms; PCSK9 Inhibitors; Proprotein Convertase 9; Protein Kinase Inhibitors

2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
    Nature communications, 2023, 05-05, Volume: 14, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Drug Resistance, Neoplasm; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neuroblastoma; Protein Kinase Inhibitors

2023
Severe Psychosis Associated With Lorlatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023, Volume: 18, Issue:7

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Psychotic Disorders

2023
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
    Nature communications, 2019, 08-09, Volume: 10, Issue:1

    Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB

2019
Reply to 'The use of buparlisib as a radiosensitiser: What about toxicity?'
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 119

    Topics: Aminopyridines; Humans; Lung Neoplasms; Morpholines; Tumor Hypoxia

2019
The use of buparlisib as a radiosentisiser: What about toxicity?
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 119

    Topics: Aminopyridines; Humans; Lung Neoplasms; Morpholines; Tumor Hypoxia

2019
Untapped potential: recognising CNS opportunities in early oncology drug development.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Drug Development; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2019
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Organophosphorus Compounds; Pneumonia; Prognosis; Pyrazoles; Pyrimidines

2019
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2019
Lorlatinib: a new treatment option for ROS1-positive lung cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2019
Lorlatinib in ROS1-positive NSCLC.
    Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:1

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Cancer science, 2020, Volume: 111, Issue:3

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Asian People; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; Sulfones

2020
18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluorodeoxyglucose F18; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrazoles; Radiopharmaceuticals

2020
Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Organophosphorus Compounds; Pyrazoles; Pyrimidines

2020
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 143

    Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Paclitaxel; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
The apoptotic effect of GSK-3 inhibitors: BIO and CHIR 98014 on H1975 lung cancer cells through ROS generation and mitochondrial dysfunction.
    Biotechnology letters, 2020, Volume: 42, Issue:8

    Topics: Aminopyridines; Cell Line, Tumor; Glycogen Synthase Kinase 3; Humans; Indoles; Lung Neoplasms; Mitochondria; Oximes; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species

2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 144

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Patient Reported Outcome Measures; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quality of Life; Surveys and Questionnaires

2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:9

    Topics: Aminopyridines; Hong Kong; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases; Republic of Korea; Taiwan

2020
A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 147

    Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2020
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Anti-cancer drugs, 2020, Volume: 31, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myc; Tumor Cells, Cultured

2020
Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:8

    Topics: Aminopyridines; Benzamides; Central Nervous System; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
A Case of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
    JAMA ophthalmology, 2020, 09-01, Volume: 138, Issue:9

    Topics: Aminopyridines; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescein Angiography; Fundus Oculi; Humans; Lung Neoplasms; Middle Aged; Pyrroles; Retina; Retinal Diseases; Tomography, Optical Coherence

2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 148

    Topics: Aminopyridines; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases; Retrospective Studies

2020
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 150

    Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.
    Anti-cancer drugs, 2020, Volume: 31, Issue:10

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Benzamides; Gene Fusion; Granuloma, Plasma Cell; Humans; Indazoles; Inflammation; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Treatment Failure; Tropomyosin

2020
Lorlatinib induced proteinuria: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:4

    Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Proteinuria; Pyrazoles

2021
Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis.
    Bosnian journal of basic medical sciences, 2021, Jun-01, Volume: 21, Issue:3

    Topics: Aminopyridines; Biomarkers, Tumor; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Humans; Lactams; Lung Neoplasms; Matrix Metalloproteinases; Piperidines; Pyrazoles; Tumor Cells, Cultured

2021
A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 150

    Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2020
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
    Molecular pharmaceutics, 2020, 12-07, Volume: 17, Issue:12

    Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages

2020
New lung-cancer drugs extend survival times.
    Nature, 2020, Volume: 587, Issue:7834

    Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis

2020
Lorlatinib CROWNed.
    Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:1

    Topics: Aminopyridines; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
Lorlatinib Outperforms Crizotinib in NSCLC.
    Cancer discovery, 2021, Volume: 11, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2021
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
    Cancer biology & therapy, 2021, 01-02, Volume: 22, Issue:1

    Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Humans; Lactams; Lung Neoplasms; Male; Mutation; Pyrazoles

2021
Lorlatinib in ALK-Rearranged Lung Cancer.
    Cancer cell, 2021, 01-11, Volume: 39, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2021
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Journal for immunotherapy of cancer, 2021, Volume: 9, Issue:2

    Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Immune Checkpoint Inhibitors; Lactams; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Nivolumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Sulfones; Time Factors; Treatment Outcome; Tumor Microenvironment

2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
    Nature communications, 2021, 02-24, Volume: 12, Issue:1

    Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles

2021
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:4

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:4

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer.
    Cancer genetics, 2021, Volume: 256-257

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Lactams; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Pyrazoles

2021
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    BMJ case reports, 2021, Apr-27, Volume: 14, Issue:4

    Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Carbazoles; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Muscle, Skeletal; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Pyrazoles

2021
Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity.
    Toxicological sciences : an official journal of the Society of Toxicology, 2021, 08-03, Volume: 182, Issue:2

    Topics: Aminopyridines; Animals; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Humans; Lactams; Lactams, Macrocyclic; Liver; Lung Neoplasms; Macaca fascicularis; Pyrazoles

2021
[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors 
and Chemotherapy].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021, May-20, Volume: 24, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Crizotinib; Female; Humans; Lactams; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Serine Endopeptidases; Sulfones

2021
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
    Drug safety, 2021, Volume: 44, Issue:8

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Portugal; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2021
[Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021, Volume: 197, Issue:7

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pharmaceutical Preparations; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; p21-Activated Kinases; Piperazines; Protein Kinase Inhibitors; Pyridines

2021
Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
    Thoracic cancer, 2021, Volume: 12, Issue:16

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Uterine Neoplasms

2021
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
    BMC pulmonary medicine, 2021, Jul-01, Volume: 21, Issue:1

    Topics: Afatinib; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrrolidinones; Quinolines

2021
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
    Anti-cancer drugs, 2021, 11-01, Volume: 32, Issue:10

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrazoles; Retrospective Studies

2021
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
    Oncology research and treatment, 2021, Volume: 44, Issue:9

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles

2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 156

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Sulfones; Taiwan; Treatment Outcome

2021
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Cancer immunology research, 2017, Volume: 5, Issue:7

    Topics: Aminopyridines; Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Macrophages; Mesothelioma; Mesothelioma, Malignant; Neoplasm Invasiveness; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor

2017
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
    Cell reports, 2017, 05-23, Volume: 19, Issue:8

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzazepines; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydrazones; Jumonji Domain-Containing Histone Demethylases; Lung Neoplasms; Methylation; Mice; Neoadjuvant Therapy; Pyrimidines; Taxoids; Transcription, Genetic

2017
Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
    Anti-cancer drugs, 2017, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Spinal Cord Neoplasms

2017
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15

    Topics: Aminopyridines; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Pyridines

2017
Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
    European journal of pharmacology, 2017, Oct-05, Volume: 812

    Topics: Aminopyridines; Animals; Benzamides; Benzo(a)pyrene; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Lung Neoplasms; Mice; Neovascularization, Pathologic

2017
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
    The American journal of case reports, 2017, Jul-17, Volume: 18

    Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Myofibroblasts; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sarcoma; Sulfones

2017
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
    Journal of medicinal chemistry, 2017, 07-27, Volume: 60, Issue:14

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Databases, Chemical; Drug Design; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats, Sprague-Dawley; Signal Transduction; Stereoisomerism; Structure-Activity Relationship

2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Dogs; Female; Humans; Lung Neoplasms; Mice; Osteosarcoma; Phosphorylation; Rhabdomyosarcoma; Sarcoma, Ewing; STAT3 Transcription Factor; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays

2017
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells.
    Biochemical and biophysical research communications, 2017, 10-21, Volume: 492, Issue:3

    Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Indazoles; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Proteolysis; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases

2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
    Cell reports, 2017, Dec-12, Volume: 21, Issue:11

    Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured

2017
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
    Redox biology, 2018, Volume: 15

    Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Daunorubicin; DNA Damage; DNA Glycosylases; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Lung Neoplasms; Piperazines; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Purines; Pyridines

2018
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
    BMC pulmonary medicine, 2018, Jan-23, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crizotinib; Cytoskeletal Proteins; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Oncogene Fusion; Pemetrexed; Progression-Free Survival; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Time Factors

2018
Lorlatinib - Induced pulmonary arterial hypertension.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 120

    Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Vascular Resistance; Walk Test; Withholding Treatment

2018
Hypermethylated CD36 gene affected the progression of lung cancer.
    Gene, 2018, Dec-15, Volume: 678

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays

2018
Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
    Cell biology international, 2018, Volume: 42, Issue:10

    Topics: A549 Cells; Aminopyridines; Benzylamines; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Hippo Signaling Pathway; Humans; Lung Neoplasms; Neoplasm Invasiveness; Nuclear Proteins; Protein Serine-Threonine Kinases; Receptors, CXCR4; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Twist-Related Protein 1; Vimentin

2018
New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
    Journal of the neurological sciences, 2018, 09-15, Volume: 392

    Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Myasthenia Gravis; Pyrazoles

2018
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018, Volume: 13, Issue:8

    Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Point Mutation; Pyrazoles

2018
Minimal Change Disease Induced by Lorlatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018, Volume: 13, Issue:8

    Topics: Adenocarcinoma of Lung; Aminopyridines; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Nephrosis, Lipoid; Pyrazoles

2018
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
    Investigational new drugs, 2019, Volume: 37, Issue:2

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disease Progression; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Prognosis; Pyrazoles; Sarcoidosis

2019
Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions.
    International journal of pharmaceutics, 2018, Oct-25, Volume: 550, Issue:1-2

    Topics: Administration, Inhalation; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cell Line, Tumor; Cyclopropanes; Drug Compounding; Drug Delivery Systems; Dry Powder Inhalers; Humans; Lung Neoplasms; Powders

2018
JIB‑04 induces cell apoptosis via activation of the p53/Bcl‑2/caspase pathway in MHCC97H and HepG2 cells.
    Oncology reports, 2018, Volume: 40, Issue:6

    Topics: Aminopyridines; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazones; Lung Neoplasms; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Suppressor Protein p53

2018
Lorlatinib: a new-generation drug for ALK-positive NSCLC.
    The Lancet. Oncology, 2018, Volume: 19, Issue:12

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Receptor Protein-Tyrosine Kinases

2018
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial.
    Chinese clinical oncology, 2019, Volume: 8, Issue:S1

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2019
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
    Science (New York, N.Y.), 2018, 12-21, Volume: 362, Issue:6421

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cellular Senescence; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytostatic Agents; Cytotoxicity, Immunologic; Humans; Immunologic Surveillance; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Purines; Pyridines; Pyridones; Pyrimidinones; Retinoblastoma Protein; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2018
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
    Clinical lung cancer, 2019, Volume: 20, Issue:2

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Crizotinib; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Neoplasm Metastasis; Organophosphorus Compounds; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome

2019
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    EBioMedicine, 2019, Volume: 41

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Dynamics Simulation; Mutation, Missense; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Software; Sulfones

2019
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Mar-15, Volume: 56

    Topics: A549 Cells; Aminopyridines; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; MicroRNAs; Reactive Oxygen Species; Telomerase

2019
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Republic of Korea; Retrospective Studies

2019
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Biochemical and biophysical research communications, 2019, 04-02, Volume: 511, Issue:2

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Serine Endopeptidases

2019
Lorlatinib for the treatment of patients with non-small cell lung cancer.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:2

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2019
Clinical Management of Adverse Events Associated with Lorlatinib.
    The oncologist, 2019, Volume: 24, Issue:8

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Severity of Illness Index; Treatment Outcome

2019
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Oncology reports, 2019, Volume: 41, Issue:5

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Imaging; Morpholines; Osteoclasts; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; X-Ray Microtomography

2019
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2019
Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
    Anti-cancer drugs, 2019, Volume: 30, Issue:10

    Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Spinal Cord Neoplasms

2019
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
    Neurology, 2019, 07-30, Volume: 93, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Spinal Cord Neoplasms; Sulfones; Treatment Outcome

2019
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Clinical lung cancer, 2019, Volume: 20, Issue:5

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Treatment Outcome

2019
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib.
    Lung cancer (Amsterdam, Netherlands), 2019, Volume: 134

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pyrazoles; Tomography, X-Ray Computed

2019
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
    BMJ case reports, 2019, Jul-24, Volume: 12, Issue:7

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Progression-Free Survival; Pyrazoles; Remission Induction; Treatment Outcome

2019
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Middle Aged; Mutation; Piperidines; Pyrazoles; Xenograft Model Antitumor Assays

2019
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
    Cancer letters, 2013, Sep-28, Volume: 338, Issue:2

    Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Down-Regulation; Drug Synergism; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Lung Neoplasms; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Ubiquitin-Protein Ligases

2013
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Cancer research, 2013, Sep-01, Volume: 73, Issue:17

    Topics: Acridines; Aminopyridines; Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Cell Proliferation; Cytochromes c; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Nude; Nitrophenols; Piperazines; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Radiation, Ionizing; Small Molecule Libraries; Sulfonamides; Survival Rate

2013
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2013, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A

2013
The current state of molecularly targeted drugs targeting HGF/Met.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1

    Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2

2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin

2014
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma

2014
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Female; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Models, Biological; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays

2015
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.
    Journal of medicinal chemistry, 2014, Dec-11, Volume: 57, Issue:23

    Topics: Amino Acid Substitution; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; High-Throughput Screening Assays; Humans; Lung Neoplasms; Methionine; Mutation; Protein Kinase Inhibitors; Threonine

2014
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Experimental dermatology, 2015, Volume: 24, Issue:7

    Topics: Adenosine Triphosphate; Aminopyridines; Angiogenesis Inhibitors; Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; CSK Tyrosine-Protein Kinase; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Janus Kinases; Lung Neoplasms; Male; Mice; Mice, Hairless; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Protein Structure, Secondary; Rats; Receptor, TIE-2; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thiophenes; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:8

    Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays

2015
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
    ACS chemical biology, 2015, Dec-18, Volume: 10, Issue:12

    Topics: Aminopyridines; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Delivery Systems; Humans; Lung Neoplasms; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proteomics; Purines; Pyridines; Signal Transduction

2015
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Aminopyridines; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Signal Transduction; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: A549 Cells; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction

2016
Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
    Molecular biology reports, 2016, Volume: 43, Issue:7

    Topics: A549 Cells; Aminopyridines; Antigens, CD; Antineoplastic Agents; Benzamides; Cadherins; DNA Methylation; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Transforming Growth Factor beta

2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Cancer discovery, 2016, Volume: 6, Issue:7

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays

2016
Lorlatinib Is Active in Drug-Resistant NSCLC.
    Cancer discovery, 2016, Volume: 6, Issue:8

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Treatment Outcome

2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Cancer discovery, 2016, Volume: 6, Issue:10

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016
Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Oncotarget, 2016, Oct-11, Volume: 7, Issue:41

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Enzyme Inhibitors; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays

2016
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Scientific reports, 2016, 09-13, Volume: 6

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Female; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Microtubules; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays

2016
The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Aminopyridines; Aurora Kinase A; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mitosis

2016
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
    Cellular oncology (Dordrecht), 2017, Volume: 40, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; Quinolones; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Sulfones; Transcriptome

2017
Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
    Nature communications, 2017, 02-08, Volume: 8

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Female; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microscopy, Fluorescence; Nanoparticles; Perfusion; Pyrroles; RAW 264.7 Cells; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2017
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 106

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Crizotinib; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retinoblastoma Binding Proteins; Small Cell Lung Carcinoma; Ubiquitin-Protein Ligases

2017
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
    Cancer biology & therapy, 2010, May-15, Volume: 9, Issue:10

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphorylation; Tyrosine; Xenograft Model Antitumor Assays

2010
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Benzoxazoles; Cell Proliferation; Colorectal Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; HT29 Cells; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2012
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays

2012
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
    Cancer letters, 2012, Dec-28, Volume: 325, Issue:2

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Culture Media, Serum-Free; Drug Synergism; Everolimus; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Recombinant Fusion Proteins; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2012
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    The American journal of pathology, 2012, Volume: 181, Issue:3

    Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2012
Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
    International journal of radiation oncology, biology, physics, 2012, Nov-15, Volume: 84, Issue:4

    Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Radiation Tolerance; Radiation-Sensitizing Agents

2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:10

    Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays

2012
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Aminopyridines; Animals; Cell Line, Tumor; Humans; Indoles; Lung Neoplasms; Mutation; Neuroendocrine Tumors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-met; Pyridones; Small Cell Lung Carcinoma; Sulfonamides

2013
Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.
    Journal of neurology, neurosurgery, and psychiatry, 1980, Volume: 43, Issue:11

    Topics: Aminopyridines; Carcinoma, Small Cell; Electrolytes; Evoked Potentials; Humans; Intercostal Muscles; Lung Neoplasms; Male; Middle Aged; Neuromuscular Diseases; Neuromuscular Junction; Synaptic Transmission; Ulnar Nerve

1980